| Autor: |
Arianne Clare C Agdamag, Daniel Gonzalez, Katie Carlson, Suma Konety, William C McDonald, Cindy M Martin, Valmiki Maharaj, Tamas Alexy |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
European Heart Journal: Case Reports |
| ISSN: |
2514-2119 |
| DOI: |
10.1093/ehjcr/ytac007 |
| Popis: |
Background The BNT162b2 vaccine received emergency use authorization from the U.S. Food and Drug Administration for the prevention of severe coronavirus disease 2019 (COVID-19) infection. We report a case of biopsy and magnetic resonance imaging (MRI)-proven severe myocarditis that developed in a previously healthy individual within days of receiving the first dose of the BNT162b2 COVID-19 vaccine. Case Summary An 80-year-old female with no significant cardiac history presented with cardiogenic shock and biopsy-proven fulminant myocarditis within 12 days of receiving the BNT162b2 COVID-19 vaccine. She required temporary mechanical circulatory support, inotropic agents, and high-dose steroids for stabilization and management. Ultimately, her cardiac function recovered, and she was discharged in stable condition after 2 weeks of hospitalization. A repeat cardiac MRI 3 months after her initial presentation demonstrated stable biventricular function and continued improvement in myocardial inflammation. Discussion Fulminant myocarditis is a rare complication of vaccination. Clinicians should stay vigilant to recognize this rare, but potentially deadly complication. Due to the high morbidity and mortality associated with COVID-19 infection, the clinical benefits of the BNT162b2 vaccine greatly outweighs the risks of complications. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
